Capital BioVentures

Capital BioVentures Launches ASCENT26: Accelerating Canada’s Next Therapeutic Breakthroughs

cbv 22 September 2026 No Comments

“The progress we’ve seen from these companies, including their transition into RIDGE, reinforces the importance of providing focused, therapeutics-specific support at the right time. "

From Canadian Discovery to Canadian Prosperity: The Advanced Therapeutics Industrial Acceleration Partnership (ATIAP) Economic Primer

cbv 21 September 2026 No Comments

The Advanced Therapeutics Industrial Acceleration Partnership (ATIAP) is a proposed four-year, $75-million national partnership between CASTL, Stem Cell Network, Capital BioVentures and OBIO®. It is designed to connect promising Canadian…

Canada has invested in science. Now it must capture the economic benefits.

cbv 16 September 2026 No Comments

The following Op-Ed was co-authored by Cate Murray, Maura Campbell, Jeff Smirle and Penny Walsh and was published in The Hill Times on September 16. What if a child born…

Yellowbird Diagnostics Completes Dosing in First-in-Human Phase 1 Trial of NeuCaVis(TM)

cbv 22 June 2026 No Comments

Yellowbird Diagnostics Inc. today announced the successful completion of dosing and imaging in its first-in-human Phase 1 clinical trial of NeuCaVis™, a novel F18 PET radiotracer designed to image inflammation.

NuvoBio Corporation Announces Research Collaboration With Protagonist

cbv 15 April 2026 No Comments

NuvoBio Corporation (NuvoBio), a developer of sequence-based generative AI for drug discovery, today announced a strategic research collaboration with Protagonist Therapeutics for up to three undisclosed targets.

Yellowbird Diagnostics Announces First Patients Dosed in Phase 1 Trial of NeuCavis(TM)

George Hilan 15 April 2026 No Comments

Yellowbird Diagnostics Inc. today announced the successful dosing and imaging of the first participants in its Phase I clinical trial of NeuCaVis™, a novel metabolic PET imaging agent designed to…

NuvoBio Selected for the Second Merck Digital Science Studio (MDSS) Cohort

George Hilan 13 March 2026 No Comments

NuvoBio, a CBV SUMMIT level company, has been selected for the prestigious MDSS accelerator program. A one of only 12 startups chosen across North America, NuvoBio is redefining peptide discovery…

ASCENT Pitch Competition Winner

George Hilan 10 March 2026 No Comments

Congratulations to our ASCENT Virtual Pitch Event winner, CEREBRO Therapeutics Inc., led by Martin Levesque! Earlier today, we had the privilege of watching our nine ASCENT companies deliver high-impact virtual…

ASCENT Cohort 1 – Pitch Competition

George Hilan 3 March 2026 No Comments

We’re excited to announce our upcoming Virtual Pitch Competition as part of the CBV ASCENT Program! Nine high-potential companies from our current cohort will take the virtual stage to pitch…

ASCENT: Fit For Funding

George Hilan 25 November 2025 No Comments

Capital BioVentures (CBV), a leading biotech accelerator, dedicated to supporting the growth of early-stage life sciences companies, is proud to announce the launch of its newest offering, the ASCENT Program...

Archives

MACS Quant 10 Configuration